Gene transfer for erectile dysfunction: Will this novel therapy be accepted by urologists?

Arnold Melman, Lorraine Rojas, George Christ

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Purpose of review: The purpose of this review is to update the results of the only phase 1 erectile dysfunction gene transfer trial and based upon those results present the outcome of a web-based survey that studied whether or not knowledgeable in the field urologists would use gene transfer in their patients once approved for use by the US Food and Drug Administration. Recent findings: The results of the clinical trials showed no transfer-related serious adverse events. The response to 10 questions of a web-based survey indicates that gene transfer as a first or second-line therapy for practicing urologists would be well accepted. Summary: Practicing, experienced urologists, after the US Food and Drug Administration approval, are willing to employ gene transfer therapies in their patients, be it men who have failed or dissatisfied with other treatments or as shown in up to one-third of men as a first therapy. That outcome portends for rapid adaptation and active participation into the medical practice for maxi-K or other specific gene transfer, stem cell, or combinations that will be developed in the future.

Original languageEnglish (US)
Pages (from-to)595-600
Number of pages6
JournalCurrent Opinion in Urology
Issue number6
StatePublished - Nov 1 2009


  • Erectile dysfunction
  • Gene transfer
  • Maxi-K
  • Naked DNA

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Gene transfer for erectile dysfunction: Will this novel therapy be accepted by urologists?'. Together they form a unique fingerprint.

Cite this